Presentation Transcript

1. Drugs Targeting the CNS • Hypnotics/Anxiolytics • Antidepressants • Neuroleptics • Parkinson • Epilepsy

2. Drugs Targeting the CNS Neurotransmitters in the CNS • Norepinephrine: • Excitory or inhibitory • Targeted by: MAO inhibitors (); tricyclic antidepressant (); amphetamines () • Acetylcholine: • Excitory (M1; N) or inhibitory (M2) • Targeted by: M inhibitors (); Acetylcholine-esterase inhibitors () • Glutamate: • Excitory • Targeted by: antiepileptics, ketamine, phencyclidine () • GABA (g-amino-butyric acid): • Inhibitory (increases gCl- and gK+, but not gNa+ => hyperpolarization (higher threshold for activation • Targeted by: hypnotics, sedative, anti-epileptics () • Dopamine: • Inhibitory • Targeted by: older neuroleptics (); anti-parkinson drugs, amphetamines () • Serotonin: • Excitory or inhibitory • Targeted by: MAO inhibitors, SSRIs, Tricyclic antidepressants, hallucinogens ()

3. Drugs Targeting the CNS Glutamate • Excitatory amino acid: • Uniformly distributed throughout the brain • Mainly derived from glutamine or glucose • Stored in synaptic vesicles • Four distinct receptors exist -(NMDA receptor subtype most significant for drug action: needs to be“co-occupied” by glycine to become activated) • Termination mainly by re-uptake into nerve terminal and astrocytes • Astrocytes convert it to glutamine (lack activity) and return it to nerve cells

4. Drugs Targeting the CNS GABA (g-amino-butyric acid) • Inhibitory amino acid: • Only found in the brain • Mainly derived from glutamate via glutamic acid decarboxylase (GAD) • Stored in synaptic vesicles • Two distinct receptors exist - GABAA and GABAB(GABAA receptor subtype most significant for drug action: mostly post-synaptic:Cl- - influx hyperpolarizes the cell => inhibitory) • Termination mainly by deamination (GABA transaminase)

5. Drugs Targeting the CNS Dopamine • Inhibitory amino acid: • Precursor to (nor)epinephrine • Termination mainly by reuptake (dopamine transporter - inhibited by Cocaine) and metabolism via MAOB and COMT • Two distinct receptor groups exist (coupled to heterotrimeric G proteins): D1-group (D1,D5: stimulate Adenylate cyclase: CNS, renal arteries) D2-group (D2,D3, D4: inhibit Adenylate cyclase: CNS) • Three main dopaminergic pathways: • Nigrostriatal (substantia nigra): motor control (Parkinson’s disease) • Mesolimbic/mesocortical: emotion and reward system • Tuberohypophysal: from hypothalamus to pituitary • (Medulla oblongata: Vomiting center: D2 receptors) • Schizophrenia: increased dopamine levels and D2 receptors

6. Drugs Targeting the CNS 5-Hydroxytryptamine (5-HT = Serotonin) • Excitatory or Inhibitory amino acid: • Generated from tryptophane • Termination mainly by reuptake and MAOB • Seven distinct receptor types exist (7-TM): 5-HT1 group (CNS, blood vessels) (cAMP) 5-HT2 group (CNS, blood vessels) (IP3/DAG) 5-HT3 group (peripheral nervous system) 5-HT4 group (enteric nervous system) • Main functions: • Intestine: increases motility • Blood vessel: constriction (large vessels) dilation (arterioles) • Nerve ending: triggers nociceptive receptors 5-HT injection causes pain (5-HT found in nettle stings) • Neurons: excites some neurons, inhibits others inhibition mostly presynaptic (inhibit transmitter release) LSD = agonist of 5-HT2A receptor

7. Drugs Targeting the CNS Sites of drug action in the CNS:

8. Drugs Targeting the CNS Anxiety: Panic disorder (panic attacks) - rapid-onet attacks of extreme fear and feelings of heart palpitations, choking and shortness of breath. Phobic anxiety is triggered by a particular object, for example; spiders, snakes, heights, or open spaces. Obsessive-compulsive disorder - uncontrollable recurring anxiety-producing thoughts and uncontrollable impulses (compulsive hand-washing, checking that doors are locked: “Monk”) Generalized anxiety disorder- extreme feeling of anxiety in the absence of any clear cause Post-traumatic stress disorder (PTSD) - recurrent recollections of a traumatic event of unusual clarity which produce intense psychological distress.

9. Hypnotics / Anxiolytics Barbiturates • Derivatives of barbituric acid • Hypnotic/anxiolytic effect discovered in the early 20th century (Veronal®, 1903) • Until the 60s the largest group of hypnotics (more hypnotic than anxiolytic) • Act by both enhancing GABA responses and mimicking GABA (open Cl-channels in the absence of GABA) => increased inhibition of the CNS (also block glutamate receptors) • High risk of dependence (severe withdrawal symptoms) • Strong depressent activity on the CNS => anesthesia • At higher doses respiratory (inhibit hypoxic and CO2 response of chemoreceptors) and cardiovascular depression =>very little use today as hypnotics (only for epilepsy and anesthesia) • Potent inducers of the P450 system in the liver => high risk of drug interactions(oral contraceptives)

10. Hypnotics / Anxiolytics Barbiturates Different barbiturates vary mostly in their duration of action • Phenobarbital • Long-acting: used for anticonvulsive therapy • Thiopental • Very short acting (very lipophilic => redistributed from the brain into the fat tissue => CNS concentration falls below effective levels: used for i.v. anesthesia • Amobarbital • Pentobarbital • Secobarbital

11. Hypnotics / Anxiolytics Benzodiazepines • Derivatives of Benzodiazepin • Valium (diazepam) in 1962 • Characteristic seven-membered ring fused to aromatic ring • Selectively activates GABA receptor operated chloride channels (bind to the benzodiazepin receptor which is part of the GABA-receptor/chloride channel complex) • Increase the affinity of GABA for its receptor • Used to treat anxieties of all kinds (phobias, preoperative anxiety, myocardial infarction (prevent cardiac stress due to anxiety…) • Significantly fewer side effects than barbiturates=> much safer => more widespread use • Cause anterograde amnesia (usefulfor minor surgeries)

12. Alprazolam Hypnotics / Anxiolytics Benzodiazepines Different benzodiazepines vary mostly in their duration of action • Chlordiazepoxide (Librium®) • introduced in 1960, first benzodiazepine • Diazepam (Valium®), Clonazepam, • Strongly anticonvulsive => therapy of status epilepticus • Lorazepam • Flunitrazepam (Rohypnol®) • Known as “date-rape drug”, “roofie” • Color- and tasteless, • Disinhibiting effect (particularly with EtOH), amnesia! • Death unlikely, but high risk of dependence • Alprazolam • Has also antidepressive properties • Triazolam • Causes paradoxical irritability (=> withdrawn in the UK)

13. Antidepressants Clinical Depression Characterized by feelings of misery, guilt, low self-esteem without cause Lack of motivation, missing drive to act Mania: opposite symptoms Unipolar depression: Depressive phase only Bipolar disorder: Depression alternates with mania “Amine hypothesis of depression”: States that a functional decrease in brain norepinephrine and/or serotonin is responsible for the disorder (maybe over-simplified, BUT => Most anti-depressive drugs facilitate the activity of these brain amines • Several drug classes • MAO inhibitors • Tricyclic antidepressants (TCAs) • Selective Serotonine Reuptake Inhibitors (SSRIs) • Misc. Heterocyclic antidepressants • Lithium (bipolar disorder only)

14. Antidepressants MAO Inhibitors: • Increase levels of norepinephrine, serotonin and dopamine by preventing their metabolism • Use is declining due to side effects (can cause fatal hypertensive crisis) => Last choice of treatment today (only if other drugs fail) • Possibility of severe food-drug interaction (“cheese reaction”: Tyramine is usually metabolized and inactivated in the gut by MAOs. MAO-inhibition allows for uptake of tyramine, which displaces norepinephrine in the storage vesicles => NE released => hypertension and cardiac arrhythmias. • Tranylcypromine • Phenelzine

15. Antidepressants Tricyclic antidepressants: • Increase levels of norepinephrine and serotonin by preventing their neuronal reuptake => extended duration of post-synaptic effects • Strong interaction with alcohol • Side effect: Sedation (H1-block) • Imipramine • Desipramine • Clomipramine • Amitriptyline • Nortriptyline

16. Antidepressants Selective Serotonin Reuptake Inhibitors (SSRIs): • Increase levels of serotonin specifically by preventing their neuronal reuptake => extended duration of post-synaptic effects • Same efficacy as TCAs, but fewer side effects • Main side effect: inhibition of sexual climax • Rare, but severe side effect: aggression, violence • Fluoxetine (Prozac®)Most widely prescribed antidepressant Sales exceed 1 bill. $ / year • Paroxetine (Paxil®) • Sertraline (Zoloft®) • Clotalopram (Celexa®)

17. Neuroleptics Schizophrenia Endogenous psychosis characterized by: Positive symptoms: thought disorder (illogical, incoherent, garbled sentences), mood inappropriation, paranoia (persecution mania) and hallucinations (voices) and Negative symptoms: withdrawal from society, flattened emotional responses, defect in selective attention (can’t distinguish between important and insignificant) Affects up to 1% of population, high suicide rate (10%) Amphetamines promote dopamine release => mimic schizophrenia “Dopamine hypothesis of schizophrenia”: States that a functional increase in brain dopamine is responsible for the disorder. In addition, 5-HT might play a role, possibly by modulating dopamine responses. Anti-psychotic drugs act as dopamine D2 (and 5-HT) receptor blockers • Several drug classes • Typical (older, pre-1980s) neuroleptics: phenothiazines, butyrophenones relieve mostly positive symptoms • Atypical (newer) neuroleptics: fewer extrapyramidal side effects relieve both positive and negative symptoms

18. Neuroleptics Classical neuroleptics: Phenothiazines • Chlorpromazine • Triflupromazine • Fluphenazine… Butyrophenones • Haloperidol • Trifluperidol • Spiroperidol

19. Neuroleptics Classical neuroleptics: Adverse effects: • Mostly extensions of dopamine-receptor antagonism (extrapyramidal effects due to dopamine blockage in the striatum): • Acute dystonia: Motor impairment, involuntary movements of face, tongue, neck.. (reversible; develops immediately after start of treatment) • Akathesia (Pseudo-Parkinsonism): motor restlessness, rigidity, tremor (reversible; develops days to month after start of treatment) • Tardive Dyskinesia: involuntary movements of most body parts (head, lips, limbs..) (irreversible; develops after extended treatment in 20-40% of patients) - main problem of classical neuroleptic therapy • Sedation (results from H1-receptor blockage) • Also block muscarinic cholinergic and a-adrenergic receptors (=> dry mouth, constipation, urinary retention) • Lactation (dopamine suppresses prolactin release) • Strong interaction with alcohol

20. Neuroleptics Atypical neuroleptics: • Inhibit 5-HT and D2 receptors • Act predominantly in the limbic system, but not in the striatum => fewer extrapyramidal side effects (might also be due to adrenergic receptor blockage) • Clozapine • Can cause agranulocytosis (=> strict monitoring required) • Olanzapine • Same efficacy as Clozapine, but no agranulocytosis • Risperidone • Olanzapine

21. Parkinson’s Disease Pathology: • Loss of dopaminergic neurons in the Pars compacta of the Substantia nigra • The excitatory influence of ACh becomes unopposed => movement disorders (tremor, muscle stiffness, slow movements, and difficulty walking) • Symptoms: stooped and rigid posture, shuffling gait, tremor, a masklike facial appearance, and "pill rolling"

22. Parkinson’s Disease Pathology: • Loss of dopaminergic suppression of the cholinergic neurons in the striatum => increased GABA output to the thalamus => suppression of stimulating input into the motor cortex => movement disorder • Treatment strategies: Dopamine replacement Dopamine agonists Cholinergic antagonists (Atropine - see Lecture 6)

23. Parkinson’s Disease Dopamine replacement: Dopamine does not cross blood-brain barrier => use of • Levodopa (L-Dopa) • Metabolic precursor of dopamine • High concentrations required, as most of L-Dopa is decarboxylated in the periphery => high concentration of peripheral dopamine => side effects! • L-Dopa combined with • Carbidopa • Dopamine decarboxylase - inhibitor • Does not cross blood-brain barrier => only peripheral effect => increases the amountof L-Dopa that reaches the brain

24. Parkinson’s Disease Dopamine agonists: Actions and side effects similar to L-Dopa • Bromocriptine • Derived from ergot alkaloids • Potent D2 agonist • Initially used to treat galactorrhoea (inhibit Prl release) • Pergolide • Pramipexole Indirect dopamine agonists: • Selegiline • Inhibitor of MAOB (mostly in the CNS => few peripheral side effects, e.g. cheese reaction etc.) • Extends half-life of dopamine

25. Epilepsy Pathology: • Group of disorders characterized by excessive excitability of neurons within the central nervous system (CNS) • Characteristic syptom is seizure • ~0.5% of population is affected Classification: • Simple (patient remains conscious, often involves brain lesions) or complex (patient looses consciousness) • Partial (only localized brain region is affected) or generalized Generalized seizures are devided into: • Tonic clonic seizures (grand mal): strong contraction of entire musculature => rigid spasm, often accompanied by salivation, defaecation and respiratory arrest. Tonic phase is followed by series of violent jerks, which slowly die out in a few minutes • Absence seizures (petite mal): often in children. Less dramatic, but more frequent (several seizures/day): patient stops abruptly what (s)he was doing and “spaces out”

26. Epilepsy Treatment strategies: Enhancement of GABA action Mostly for partial and generalized convulsive seizures (not effective in absence seizures) • Carbamazepine • Benzodiazepine => increases Cl--influx in response to GABA => counteracts depolarization • Tiagabin • Prevents GABA re-uptake Inhibition of sodium channels • Phenytoin • Blocks voltage-gated Na+-channels in the inactivated (refractory) state => preferential inhibition of high-frequency discharges(very limited effect on normal frequency excitation = “use-dependent inhibition”) • Eliminated following zero-order kinetics • Used for convulsive seizures (not effective in absence seizures) • gingival hyperplasia (fairly high percentage)

27. Epilepsy Treatment strategies: Inhibition of calcium channels • Ethosuximide • Blocks T-type channels • Drug of choice for absence seizures • Valproate • Exact mechanism unclear (causes GABA increase in the brain) • Useful for convulsive and absence seizures • Teratogenic • Hepatotoxic (elevated liver enzymes, even fatal hepatic failure)

28. Ethanol Most widely consumed “drug”: 1 drink = ~ 8-12g ethanol (= 0.17-0.26 mole) => not unusual to consume >1mole/session (equivalent to ~ 0.5 kg of most other drugs) • Biological effects Resembles actions of general, volatile anesthetics Acts on many different levels: • Low concentrations: • enhancement of excitatory effects of N-ACh and 5-HT3 receptors => agitation • Higher concentrations: • Inhibition of neurotransmitter release by blocking Na+ and Ca2+ channels • Inhibition of NMDA receptor function • Enhancement of GABA-mediated inhibition (similar to benzodiazepines) Peripheral effects: • Cutaneous vasodilation (heat loss!!) • Increased salvary and gastric secretion (=> hunger) • Increased glucocorticoid release • Inhibition of anti-diuretic hormone (ADH) secretion => diuresis • Inhibition of Oxytocin release (=> delay of labor induction) • Long-term effect: • Liver damage: increased fat accumulation due to increased “stress” => increased release of fatty acids from fat tissue, and impaired fatty acid oxidation due to “metabolic competition” • Chronic malnutrition (ethanol satisfies the “caloric requirement”, but no vitamins etc.)